WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2013046133) PHARMACEUTICAL COMPOSITIONS OF N-METHYL-2-[3-((E)-2-PYRIDIN-2-YL-VINYL)-1H-INDAZOL-6-YLSULFANYL]-BENZAMIDE
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2013/046133    International Application No.:    PCT/IB2012/055126
Publication Date: 04.04.2013 International Filing Date: 26.09.2012
IPC:
A61K 9/28 (2006.01), A61K 31/4439 (2006.01)
Applicants: PFIZER INC. [US/US]; 235 East 42nd Street New York, New York 10017 (US)
Inventors: GIERER, Daniel Scott; (US).
MORGADO, James Eric; (US).
MURPHY, Brendan John; (US).
SIMMONS, Daryl Michael; (US)
Agent: KLEIMAN, Gabriel L.; 235 East 42nd Street Pfizer Inc. New York, New York 10017 (US)
Priority Data:
61/541,525 30.09.2011 US
Title (EN) PHARMACEUTICAL COMPOSITIONS OF N-METHYL-2-[3-((E)-2-PYRIDIN-2-YL-VINYL)-1H-INDAZOL-6-YLSULFANYL]-BENZAMIDE
(FR) COMPOSITIONS PHARMACEUTIQUES DE N-MÉTHYL-2-[3-((E)-2-PYRIDIN-2-YL-VINYL)-1H-INDAZOL-6-YLSULFANYL-BENZAMIDE
Abstract: front page image
(EN)The present invention relates to pharmaceutical compositions containing axitinib, which is known as N-methyl-2-[3-((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylsulfanyl]- benzamide or 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2- yl)ethenyl]indazole, or crystalline forms thereof, that protect axitinib from degradation, including photodegradation, as well as the therapeutic use of such compositions. The present invention also relates to novel photodegradants of axitinib.
(FR)La présente invention concerne des compositions pharmaceutiques d'axitinib, qui est connu comme le N-méthyl-2-[3-((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylsulfanyl-benzamide ou 6-[2-(méthylcarbamoyl)phénylsulfanyl]-3-E-[2-(pyridin-2-yl)éthényl]indazole, ou des formes cristallines de celui-ci, qui protègent l'axitinib de la dégradation, notamment la photodégradation, ainsi que l'utilisation thérapeutiques de ces compositions. La présente invention concerne également de nouveaux agents de photodégradation d'axitinib.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)